TransMedics Group, Inc. (NASDAQ:TMDX) Short Interest Update

TransMedics Group, Inc. (NASDAQ:TMDX) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 8,430,000 shares, a growth of 30.9% from the October 15th total of 6,440,000 shares. Based on an average trading volume of 1,390,000 shares, the days-to-cover ratio is presently 6.1 days.

Analyst Ratings Changes

A number of research firms have commented on TMDX. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Oppenheimer lowered their price objective on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research report on Tuesday, October 29th. Piper Sandler restated an “overweight” rating and issued a $180.00 target price on shares of TransMedics Group in a research note on Tuesday, October 29th. Robert W. Baird reduced their price objective on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, October 29th. Finally, Needham & Company LLC lowered their target price on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $144.80.

TransMedics Group Stock Performance

TMDX traded down $7.88 during trading on Friday, hitting $80.48. The stock had a trading volume of 2,305,980 shares, compared to its average volume of 969,652. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a 50 day moving average price of $125.63 and a 200-day moving average price of $139.09. TransMedics Group has a one year low of $63.85 and a one year high of $177.37. The firm has a market cap of $2.70 billion, a price-to-earnings ratio of 85.62 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same period in the previous year, the firm posted ($0.12) EPS. The company’s revenue was up 63.7% compared to the same quarter last year. As a group, research analysts predict that TransMedics Group will post 1.07 EPS for the current year.

Insiders Place Their Bets

In other TransMedics Group news, insider Nicholas Corcoran sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the transaction, the insider now directly owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. The trade was a 32.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $9,457,269.06. This trade represents a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,958 shares of company stock worth $5,230,528 over the last three months. 7.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Amalgamated Bank boosted its stake in shares of TransMedics Group by 6.7% in the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after buying an additional 70 shares during the period. Pitcairn Co. lifted its position in shares of TransMedics Group by 1.5% during the 1st quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock valued at $398,000 after acquiring an additional 78 shares during the period. Harbour Capital Advisors LLC grew its holdings in shares of TransMedics Group by 1.7% during the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after purchasing an additional 81 shares in the last quarter. Signaturefd LLC increased its position in shares of TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the period. Finally, Arizona State Retirement System raised its stake in TransMedics Group by 2.1% in the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after purchasing an additional 186 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.